Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

KRAS G12C mutant protein inhibitor, pharmaceutical composition comprising same, preparation method and application

A compound and pharmaceutical technology, applied in the field of preparation of KRASG12C mutant protein inhibitor and its pharmaceutical composition, can solve the problems of prolonging protein activation time and prolonging signal transduction cells

Active Publication Date: 2021-10-22
SUZHOU INTRAGRAND PHARMA CO LTD
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Any mutation in RAS that affects the ability of RAS to interact with GAP or to convert GTP back to GDP will result in prolonged activation of the protein and thus a prolonged signaling cell, prompting the cell to continue growing and dividing
Because this signaling causes cells to grow and divide, overactive RAS signaling can eventually lead to cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • KRAS G12C mutant protein inhibitor, pharmaceutical composition comprising same, preparation method and application
  • KRAS G12C mutant protein inhibitor, pharmaceutical composition comprising same, preparation method and application
  • KRAS G12C mutant protein inhibitor, pharmaceutical composition comprising same, preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1： example 1

[0191] Embodiment 1: the synthesis of example 1 compound and its intermediate

[0192] Referring to the synthesis method of WO2019141250A1, the synthetic routes of Intermediate J and Intermediate K are designed as follows:

[0193]

[0194] Synthesis of compound 1-2:

[0195] Compound 1-1 (1 g, 7.09 mmol, 1 eq) and compound 1-1A (1.26 g, 9.21 mmol, 982.46 uL, 1.3 eq) were dissolved in a solution in DCM (20 mL), TEA (1.43 g, 14.17 mmol , 1.97mL, 2eq), the mixture was stirred at 15-20°C for 2 hours. The mixture was diluted with DCM (30 mL), washed with 5% hydrochloric acid (50 mL) and saturated brine (30 mL), the organic phase was separated, washed with Na 2 SO 4 It was dried, filtered and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (0-100% gradient elution, petroleum ether / ethyl acetate) to obtain compound 1-2 as a yellow solid (660 mg, yield 38.62%).

[0196] 1 H-NMR (400MHz, CDCl 3 )δ=8.58(s,1H),7.23-7.15...

example 1

[0238] Example 1b (1.5 mg, 13.20% yield, 98.9% purity). 1 H NMR (400MHz, CDCl 3 )δ=7.41-7.31(m,3H),7.24-7.17(m,1H),7.06(d,J=7.6Hz,1H),6.90(s,1H),6.78-6.69(m,2H),6.67 -6.57(m,1H),6.40(dd,J=1.6,16.8Hz,1H),5.85-5.78(m,1H),4.09-3.78(m,8H),3.71(s,3H),2.73-2.63 (m, 1H), 1.22 (d, J=6.8Hz, 3H), 1.11 (d, J=6.8Hz, 3H). MS: (M+H): 612.1.

[0239] The second preparation route of example 1a and example 1b is as follows:

[0240]

[0241] Synthesis of Compound 1-13:

[0242] Intermediate J (2g, 6.11mmol, 1eq), 2-isopropylphenylboronic acid (2g, 12.22mmol, 2eq), Cu 2 O (1.75g, 12.22mmol, 2eq) was dissolved in methanol (40mL), the mixture was stirred at 50°C for 2 hours under an oxygen atmosphere, concentrated under reduced pressure, diluted with water (80mL), extracted with ethyl acetate (80mL*2), and combined The organic phase was washed with saturated brine (50 mL), anhydrous Na 2 SO 4 It was dried, filtered, concentrated under reduced pressure, and purified by prep-TLC (petroleu...

Embodiment 2

[0257] Embodiment 2: the preparation of example 2 compound

[0258] Example 1a is demethylated by boron tribromide to obtain example 2 compound, MS: (M+H): 598.1

[0259]

[0260] Example 1a (120.0 mg, 182.47 μmol, 1 eq) was dissolved in DCM (3 mL), and BBr was added at 0 °C 3 (0.3mL), stirred for 1 hour, and the reaction solution was poured into iced NaHCO 3 (20mL), added water (10mL) and dichloromethane extraction (10mL*2), combined organic layer, dried over anhydrous sodium sulfate, concentrated crude product, preparative HPLC purified to obtain target product Example 2 (6.9mg, yield 6.1%) ).

[0261] 1 H NMR (400MHz, CDCl 3 )=7.39-7.31(m,2H),7.23-7.09(m,2H),7.00(d,J=6.4Hz,1H),6.91(s,1H),6.72-6.52(m,3H),6.45- 6.34(m,1H),5.85-5.78(m,1H),4.01-3.61(m,8H),2.65(q,J=6.7Hz,1H),1.21(d,J=6.8Hz,3H),1.10 (d,J=6.8Hz,3H).LCMS:(M+H) + :598.0

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a compound with irreversible inhibitor activity of G12C mutant KRAS protein, and a racemate, a stereoisomer, a pharmaceutically acceptable salt, a polymorphic substance or a solvate of the compound. The structure of the compound is shown as a formula (I) in the specification. Also provided are methods related to the preparation and use of the compounds, a pharmaceutical composition comprising the compounds, and a method of modulating G12C mutant KRAS protein activity for the treatment of conditions such as cancer.

Description

[0001] This application requires the prior ownership of the patent application number 202010313445.0 submitted by the applicant to the State Intellectual Property Office of China on April 20, 2020, and the invention name is "KRAS G12C mutant protein inhibitor and its pharmaceutical composition, preparation method and use" Priority of application. The entirety of this application is incorporated by reference into this application. Technical field [0002] The invention belongs to the field of pharmaceuticals, and specifically relates to a class of KRAS G12C mutant protein inhibitors and their pharmaceutical compositions, preparation methods and uses. Background technique [0003] RAS gene mutation is a gene with high mutation frequency in diseases such as tumors. Targeted intervention for its mutated protein is an important goal in the development of drugs for diseases related to mutated Ras protein. RAS represents a group of closely related monomeric globular proteins (21 k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04C07D519/00A61K31/519A61P35/00A61P35/02
CPCC07D471/04C07D519/00A61P35/00A61P35/02Y02P20/55
Inventor 朱加望姚瑶
Owner SUZHOU INTRAGRAND PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com